New York’s No-Fault Automobile Liability Insurance Dispute Process

No-fault automobile liability insurance coverage, also known as personal injury protection insurance (“PIP Insurance”), provides coverage for personal injuries arising from accidents involving the insured driver.[1] PIP Insurance provides coverage to the insured driver, passenger, or pedestrians injured in the accident, regardless of whether the insured driver is at fault.[2] As required under New York State’s motor vehicle insurance law, New York Insurance Law Article 51, the required coverage provides payments for the basic economic loss for each person injured.[3] Basic economic loss is defined as up to $50,000 for medical bills, lost earnings, and related expenses, as a result of the accident.[4] As part of New York Insurance Law Article 51, all disputes between insurance carriers and insureds, injured parties, or medical providers to those injured in an accident are to be settled through an arbitration process.[5] The rules and procedures for the arbitration process are promulgated by the New York State Superintendent of Insurance.[6] The arbitration proceeding is administered by the American Arbitration Association.[7] This post was originally published on the Cardozo Journal of Conflict Resolution website on November 17, 2021. The original post can be accessed via the Archived Link button above

Commencement Program and Complete Video Recording

Maurice A. Deane School of Law Ceremony, featuring Marc L. Hamroff ’83, managing partner of Moritt Hock & Hamroff LLP, and Judge A. Gail Prudenti, the School of Law’s executive director of the Center for Children, Families and the Law and special advisor to Dean Eric Lane

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation : Data From ROCKET AF

M. Kaste on työryhmän ROCKET AF Steering Comm jäsen.Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intention-to-treat population. The median age was 73 years, and the mean CHADS(2) score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P= 75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, approximate to 7 in 10 deaths were cardiovascular, whereasPeer reviewe

Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

<p>Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p> <p>Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p> <p>Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.</p&gt

New York’s No-Fault Automobile Liability Insurance Dispute Process

No-fault automobile liability insurance coverage, also known as personal injury protection insurance (“PIP Insurance”), provides coverage for personal injuries arising from accidents involving the insured driver. PIP Insurance provides coverage to the insured driver, passenger, or pedestrians injured in the accident, regardless of whether the insured driver is at fault. As required under New York State’s motor vehicle insurance law, New York Insurance Law Article 51, the required coverage provides payments for the basic economic loss for each person injured. Basic economic loss is defined as up to $50,000 for medical bills, lost earnings, and related expenses, as a result of the accident. As part of New York Insurance Law Article 51, all disputes between insurance carriers and insureds, injured parties, or medical providers to those injured in an accident are to be settled through an arbitration process. The rules and procedures for the arbitration process are promulgated by the New York State Superintendent of Insurance. The arbitration proceeding is administered by the American Arbitration Association. This post was originally published on the Cardozo Journal of Conflict Resolution website on November 17, 2021. The original post can be accessed via the Archived Link button above